Bavarian Nordic CEO 'Seeking Big Pharma partner' For RSV Vaccine Program
Phase II trials of Bavarian Nordic’s MVA-BN RSV prophylactic vaccine suggest it boosts memory responses against RSV in patients with a poor underlying immunity. Phase III trials may begin in 2020.
You may also be interested in...
Nigeria's monkeypox outbreak represents opportunity for Danish company still looking to overcome cancer vaccine setback.
A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.
Created when BetterLife bought Altum at end-July, the merged entity will now focus on advancing the acquired group’s lead asset, an inhaled form of its patented interferon a2b product, as an early treatment for COVID-19.